Vetter and Rentschler strengthen strategic alliance

Published: 29-Apr-2021

The collaboration was initiated in 2020 with the intent to enable clients to bring their products to patients easier and faster

Rentschler Biopharma and Vetter have announced key steps forward in their strategic collaboration. The companies have strengthened the established framework for their alliance and set up a governance structure, as well as guidelines for their joint approach across functions. In parallel to starting their first joint client projects, they are also working closely on existing projects and related topics.

The collaboration was initiated in 2020 with the intent to enable clients to bring their products to patients easier and faster. Its established framework consists of an overall collaboration agreement that regulates the intended contributions of both parties to generate added value for clients and patients around the world.

The companies have implemented further operational agreements and guidelines between various departments, covering key standards for joint approaches as well as core inputs and processes across both organisations to align interfaces and optimise services for the client’s convenience and long-term planning.

“The formation of the mutual agreements and alignment on a client approach were foundational steps that both Vetter and Rentschler Biopharma identified early in our exploration of this strategic alliance,” said Vetter MD Peter Soelkner. “We look forward to the new progress that this step will facilitate.”

The organisations have defined the target markets for their collaboration, focusing on Europe, US and the Asia-Pacific, as well as emerging markets. They are working closely together to approach clients who may derive value from the partnership. The pair say they have initiated their first joint client projects, and additional projects are in discussion.

“We are very interested to see how the experience gained in these initial projects will further enhance our strategic alliance,” said Dr Frank Mathias, CEO of Rentschler Biopharma. “These client engagements will provide valuable insights for our teams to leverage in refining the alignment of our processes and approaches.”

Both companies still aim to independently address and service current and clients while they pursue further cooperative integration.

Trending Articles

You may also like